SCHEMBL25291998

SCHEMBL25291998

Ic1cnn2cc(-c3cnn(C4CC4)c3)cnc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAB2 O43741 1/20 0.38
PRKAG1 P54619 1/20 0.38
PRKAA2 P54646 1/20 0.38
PRKAA1 Q13131 1/20 0.38
PRKAG3 Q9UGI9 1/20 0.38
PRKAG2 Q9UGJ0 1/20 0.38
PRKAB1 Q9Y478 1/20 0.38
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
PI4KA P42356 1/20 0.38
PIK3CG P48736 1/20 0.38
PI4KB Q9UBF8 1/20 0.38
RET P07949 1/20 0.38
KDR P35968 3/20 0.37
FLT1 P17948 2/20 0.37
FLT4 P35916 2/20 0.37
KIT P10721 1/20 0.37
IRAK1 P51617 2/20 0.36
NTRK1 P04629 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25247273 0.78 PIK3CD (0.42) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL31487791 0.77 MAP4K3 (0.44) IRAK1NTRK1MAP4K3IRAK4PAK1
SCHEMBL13818129 0.73 KDR (0.59) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL25424497 0.73 KDR (0.47) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL25289913 0.72 ALK (0.42) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL3319815 0.71 KDR (0.61) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL31487845 0.69 MET (0.37) RETCLK2GSK3BDYRK1A
SCHEMBL15594544 0.68 MAP4K1 (0.43) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL22270764 0.67 IRAK4 (0.44) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL25426296 0.67 CSNK2B (0.32) CDK2IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600719-B2 Salt inducible kinase inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2026-04-14 US disclosed
EP-4660192-A1 SALT INDUCIBLE KINASE INHIBITORS The General Hospital Corporation (US) 2025-12-10 EP disclosed
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION 2024-01-25 US disclosed
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION 2024-01-25 US disclosed
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION 2024-01-25 US disclosed
EP-4192459-A1 SALT INDUCIBLE KINASE INHIBITORS The General Hospital Corporation (US) 2023-06-14 EP disclosed
WO-2022031928-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2022-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600719-B2 Salt inducible kinase inhibitors GRK6, SGK1, CSNK1A1 PRKAB2 337/4885PRKAG1 247/4885PRKAA2 306/4885
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS SGK1, SGK2, SIK1 PRKAB2 190/4885PRKAG1 164/4885PRKAA2 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.